NASDAQ:CALC CalciMedica 3/27/2025 Earnings Report $0.70 +0.01 (+0.88%) As of 01:13 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast CalciMedica EPS ResultsActual EPS-$0.34Consensus EPS -$0.48Beat/MissBeat by +$0.14One Year Ago EPSN/ACalciMedica Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACalciMedica Announcement DetailsQuarterDate3/27/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile CalciMedica Earnings HeadlinesCalciMedica, Inc.: CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate UpdatesMay 12 at 5:15 PM | finanznachrichten.deCalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate UpdatesMay 12 at 7:00 AM | prnewswire.comThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on day one often end up holding the bag when early insiders cash out. Analyst Michael Robinson believes the smarter move is a little-known partner company supplying critical technology to Elon's so-called 'Project Unlimited' - an undertaking he says could unlock $100 trillion in potential growth. You need to be positioned before the June 2026 listing date.May 14 at 1:00 AM | Weiss Ratings (Ad)CalciMedica (CALC) to Release Quarterly Earnings on WednesdayMay 11 at 3:51 AM | americanbankingnews.comCalciMedica, Inc. Common Stock (CALC)May 1, 2026 | nasdaq.comCalciMedica (CALC) price target decreased by 24.39% to 10.54March 27, 2026 | msn.comSee More CalciMedica Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CalciMedica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CalciMedica and other key companies, straight to your email. Email Address About CalciMedicaCalciMedica (NASDAQ:CALC), Inc. (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses. The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia. Early-phase data suggest that CRAC channel inhibition can reduce inflammatory cytokine release and support organ function in critically ill patients. CalciMedica pursues a development strategy that combines rigorous clinical evaluation with strategic collaborations to expedite potential regulatory approvals and commercialization. Operating primarily in the United States, the company works closely with academic centers and healthcare organizations to advance its pipeline. By targeting calcium signaling in innate immune cells, CalciMedica aims to fill unmet medical needs in acute inflammatory diseases and improve outcomes for high-risk patient populations.View CalciMedica ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nebius Upside Expands as AI Feedback Loop IntensifiesOklo Stock Could Be Ready for Another Massive RunAmazon vs. Alibaba: One Is Clearly The Better Value Play right NowD-Wave Earnings Looked Weak, But Investors May Be Missing ThisThe Great SPR Arbitrage: An Oil Market Glitch Fuels Sector GainsA New Focus for GoPro: Is a Takeover in the Frame?Chime Finally Turns Profitable—But Risks Remain Upcoming Earnings Mizuho Financial Group (5/15/2026)Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
